$LRMR SEC Filings

Filed On	Filing
01 Oct 2026	Form 4: Harlow John B. Jr., President and COO Received 50,000 shares as a grant or award · Granted 800,000 Stock Option (Right to Buy)
01 Oct 2026	Form 3: Harlow John B. Jr., President and COO No securities owned
29 Sep 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers The Board of Directors (the “Board”) of Larimar Therapeutics, Inc. (the “Company”) appointed John B. Harlow, Jr. as the Company’s President and Chief Operating Officer pursuant to the terms of an employment agreement with Mr. Harlow (the...
04 Aug 2026	10-Q
04 Aug 2026	8-K: Results of Operations and Financial Condition; Other Events
08 Jul 2026	Form 4: Hamilton Thomas Edward, Director Bought 50,000 shares ($167K)
29 Jun 2026	8-K: Other Events
20 May 2026	Form 4: Flynn James E, Director and 1 other Granted 55,150 Stock Option (Right to Buy)
20 May 2026	Form 4: Leff Jonathan S, Director Granted 55,150 Stock Option (Right to Buy)
20 May 2026	Form 4: Sherman Jeffrey W, Director Granted 55,150 Stock Option (Right to Buy)
20 May 2026	Form 4: Truitt Joseph, Director Granted 55,150 Stock Option (Right to Buy)
20 May 2026	Form 4: Thomas Frank E, Director Granted 55,150 Stock Option (Right to Buy)
20 May 2026	Form 4: Hamilton Thomas Edward, Director Granted 55,150 Stock Option (Right to Buy)
19 May 2026	8-K: Submission of Matters to a Vote of Security Holders
14 May 2026	SCHEDULE 13G/A
14 May 2026	10-Q
14 May 2026	8-K: Results of Operations and Financial Condition; Other Events
30 Apr 2026	SCHEDULE 13G/A
20 Apr 2026	ARS
20 Apr 2026	Proxy statement: annual meeting on May 19, 2026 say-on-pay vote

Comments